[1] ZHENG Y, WANG ZZ.The interpretation of global colorectal cancer epidemic data[J]. Chinese Journal of Epidemiology(中华流行病学杂志), 2021, 42(1): 149-152. [2] HUANG SF, LING XL.Research progress of PD-1/PD-L1 inhibitors combined with antiangiogenic agents in the treatment of advanced triple-negative breast cancer[J]. Cancer Research on Prevention and Treatment(肿瘤防治研究), 2021, 48(1): 75-81. [3] ZENG HM, LUO LQ, CAI Y, et al.Clinical efficacy and safety of PD-1 in the treatment of advanced primary liver cancer[J]. Chinese and Foreign Medical Research(中外医学研究), 2021, 19(3): 27-29. [4] ZHANG SY, WANG Y.Progress of programmed death receptor 1 and programmed death receptor ligand 1 inhibitors in the treatment of small cell lung cancer[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2021, 43(1): 98-103. [5] LIUDMILA VF, KIRILL VL, NATALIA BM, et al.Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma[J]. Annals of Hematology, 2021, 33: 528-536. [6] ZHU D, LI YY, SONG YQ, et al.The clinical research progress of sintilimab, an inhibitor of PD-1[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020, 40(1): 120-123. [7] WANG J, FEI K, JING H, et al.Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit[J]. Mabs Austin, 2019, 11(8): 1443-1451. [8] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA -a Cancer Journal for Clinicians, 2018, 68(6): 394-424. [9] SHI LL, LIU XA, SHAN GY.Preliminary analysis of efficacy and safety and predictors of efficacy in patients with advanced colorectal cancer after failure of standard retroline therapy with apatinib[J]. Chinese Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2020, 25(12): 1388-1394. [10] LI WH, ZHANG W.The progress of chemotherapy in advanced colorectal cancer[J]. China Oncology(中国癌症杂志), 2015, 25(11): 877-889. [11] ZHOU H, ZHANG Y, ZHANG N, et al.Treatment and clinical characteristics of advanced colorectal cancer[J]. Journal of Modern Oncology(现代肿瘤医学), 2016, 24(7): 1075-1079. [12] OVERMAN MJ, S L, KYM W, et al. Durable clinical benefit with nivolumab plusipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. Journal of Clinical Oncology, 2018, 36(8): 773-779. [13] WANG Y, ZHOU S, YANG F, et al.Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis[J]. JAMA Oncology, 2019, 5(7): 1008-1019. [14] MAN J, RITCHIE G, LINKS M, et al.Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis[J]. Asia Pacific Journal Clinical Oncology, 2018, 14(3): 141-152. [15] XU YQ, LIU Y.Research progress of immune-related adverse reactions of PD-1/PD-L1 inhibitors[J]. Journal of Practical Oncology(实用肿瘤杂志), 2020, 35(6): 491-494. [16] SIBAUD V.Dermatologic reactions to immune checkpoint inhibitors skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018, 19(3): 345-361. [17] SI XY, HE CX, ZHANG L, et al.Suggestions for the diagnosis and treatment of cutaneous adverse reactions related to immune checkpoint inhibitors[J]. Chinese Journal of Lung Cancer(中国肺癌杂志), 2019, 22(10): 639-644. |